908 Devices Q4 Earnings Call Highlights

908 Devices (NASDAQ:MASS) reported fourth-quarter and full-year 2025 results that management said reflected continued momentum from its strategic transformation, including stronger adoption of its handheld chemical analysis devices and improved profitability metrics.

Fourth-quarter growth driven by XplorIR and new VipIR launch

CEO and co-founder Kevin J. Knopp said the company generated $17.4 million in revenue from continuing operations in the fourth quarter, up 21% year over year. He attributed the growth primarily to continued demand for the company’s XplorIR gas identification device among firefighters and hazardous materials response teams, strong early demand for the company’s new VipIR product, and ongoing adoption among U.S. state and local customers.

CFO Joseph H. Griffith noted that, following the sale of the company’s desktop portfolio in the first quarter of 2025, the figures discussed on the call reflect continuing operations only, with desktops reported as discontinued operations.

Griffith said handheld product and service revenue was $16.0 million in the quarter, up 18%, driven mainly by the company’s FTIR products. He said the company shipped more than 40 VipIR units in the quarter, generating over $3 million in revenue, while XplorIR more than doubled its placements compared with the prior-year period. MX908 product and service revenue was described as relatively flat, as higher U.S. orders offset fewer international device shipments.

In total, the company shipped 224 devices in the fourth quarter, bringing its installed base to 3,736, Griffith said.

Profitability improved as cost actions flowed through results

Management highlighted a key milestone in the quarter: positive adjusted EBITDA of $0.7 million, compared with an adjusted EBITDA loss of $4.0 million in the prior-year period. Knopp said the improvement validated the structural initiatives implemented during the company’s transformation.

Griffith reported gross profit of $9.2 million and gross margin of 53% in the fourth quarter, up from 47% a year earlier, driven by higher volume and a channel mix shift toward state and local and defense sales. Adjusted gross margin was 57%, up about 530 basis points year over year.

Operating expenses totaled $6.1 million in the quarter versus $23.4 million in the prior year period. Griffith said the year-over-year change was largely due to non-cash items in the fourth quarter of 2024, including a $10.1 million goodwill impairment charge and a $5.1 million reduction in the fair value of contingent consideration. Excluding those items, he said operating expenses decreased by $2.0 million due to lower headcount and facility expenses.

Net income from continuing operations was $4.4 million, compared with a net loss of $16.0 million in the prior-year quarter, with Griffith citing improved gross margins, lower operating expenses, and the absence of prior-year non-cash charges.

Full-year results: higher revenue mix from recurring and state/local channels

For the full year 2025, Knopp said the company delivered $56.2 million in revenue from continuing operations, up 18% year over year. He also highlighted recurring revenue growth of 22%, representing 35% of 2025 revenue, driven by service, support, software, and accessories.

Griffith added that state and local sales channel revenue grew 38% to approximately $24 million, representing 43% of total 2025 revenue. He said those deals are generally smaller and more frequent, providing a more predictable balance against larger, “potentially lumpy” federal and military enterprise sales.

On profitability, Griffith reported a full-year net loss from continuing operations of $33.3 million, compared with $53.1 million in 2024, and an adjusted EBITDA loss of $9.6 million, a 39% reduction versus 2024.

The company ended 2025 with $113 million in cash equivalents and marketable securities and no debt outstanding, according to management. Griffith said the company generated approximately $0.9 million of cash in the fourth quarter, primarily related to collections and working capital timing.

Operational and product updates: contracting consolidation, international traction, and platform enhancements

Knopp said the company consolidated U.S. federal contracting partners from four to one in the fourth quarter to improve procurement efficiency and forecasting predictability. For 2026, 908 Devices will work with Mountain Horse Solutions, which Knopp described as a procurement specialist serving U.S. government and military customers with contracting, logistics, and kitting capabilities.

Internationally, Knopp said 27% of full-year 2025 revenue came from outside the U.S., up from 25% in 2024. He cited increased defense budgets among NATO countries and said the company ships chemical detection devices to countries including Poland, the Czech Republic, Finland, Ukraine, and others in the region.

Knopp also highlighted product developments during 2025:

• VipIR: Launched in July 2025, combining FTIR and Raman spectroscopy with proprietary Smart Spectral Processing and integration with the Team Leader app for sharing results.
• MX908 improvements: New “Tick Hunter” mission mode and expanded drug detection targets, including medetomidine.
• Next-gen mass spec platform: Knopp said the next-generation MX platform remains on track for a commercial launch later in 2026, though he did not provide specific timing details.

During the Q&A, Knopp also discussed longer-term integration opportunities with robotics and autonomous systems, referencing collaborations and demonstrations that paired the company’s sensing technology with quadruped robots for hazardous chemical detection.

2026 outlook: 15% to 20% revenue growth and margin expansion target

For 2026, Griffith guided to revenue of $64.5 million to $67.5 million, representing 15% to 20% growth over 2025. The outlook includes expectations for handheld product and service revenue of $59.5 million to $61.5 million (13% to 17% growth), approximately $3 million in OEM and funded partnerships, and $2 million to $3 million of revenue from the Department of Defense AVCAD program, “likely in the second half of 2026.”

Griffith said the company expects adjusted gross margins in the mid-to-high 50% range and is targeting at least 100 basis points of expansion, supported by higher volume, the first full year of manufacturing in Danbury, Connecticut, and insourcing initiatives tied to precision machining capabilities.

On profitability, Griffith said the company expects to cut its 2025 adjusted EBITDA loss roughly in half in 2026, to the mid-single digit millions, while making targeted investments in selling and marketing to support growth.

Knopp said the company entered 2026 with a late-stage pipeline “double the size” it was at the start of 2025, and reiterated management’s focus on scaling proven platforms, extending platform leadership, and strengthening revenue durability through recurring revenue and longer-term programs.

About 908 Devices (NASDAQ:MASS)

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.